Delirium within the intensive care unit (ICU) is associated with poor outcomes such as
increased mortality, ICU and hospital length of stay (LOS), and time on mechanical
ventilation. Benzodiazepine (BZD) exposure is an independent risk factor for development of
delirium. Reversal of hypoactive delirium represents a potential opportunity for reducing
duration of delirium and subsequent complications.
This is a single-center randomized, double-blind, placebo-controlled study of critically ill
adult patients with benzodiazepine-associated hypoactive delirium. The hypothesis is that
flumazenil continuous infusion may reverse hypoactive delirium associated with BZD exposure
and thereby reduce duration of delirium and ICU LOS.